Edgewise Therapeutics, Inc. (NASDAQ:EWTX) saw its shares close 3% higher on Tuesday, January 13. The increase followed the company's release of a corporate update detailing its priorities for 2026.
Among the milestones highlighted for the current year are top-line findings for Sevasemten expected by the fourth quarter. This therapy aims to become the first approved treatment for Becker disease patients. Additionally, Phase 2 results for EDG-7500, a selective cardiac sarcomere modulator targeting hypertrophic cardiomyopathy (HCM), are anticipated in the first half of the year.
The stock has surged over 57% in the last three months, as of the close on January 12. It holds a one-year average share price target of $38.14, indicating a potential upside of 58.06% from that date. Wall Street analysts maintain a consensus Strong Buy rating on Edgewise.
Several research firms have recently covered the stock. On December 24, Stifel Nicolaus maintained a Hold rating with a $16 price target. Also on December 24, JPMorgan analyst Tessa Romero reiterated the firm's Overweight rating on the shares.
Edgewise Therapeutics is a biopharmaceutical company focused on developing treatments for muscular dystrophies and cardiac diseases.